Retrospective Evaluation of clinicopathologic correlations and genetic analysis in patients with Tumor Induced Osteomalacia (TIO)

Retrospective Evaluation of clinicopathologic correlations and genetic analysis in patients with Tumor Induced Osteomalacia (TIO) - REACT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040835

Enrollment

Registered

2026-07-15

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M83.8

Interventions

Group 1: Retrospective cohort of patients with histologically confirmed phosphaturic mesenchymal tumors (PMTs) and clinically documented tumor-induced osteomalacia (TIO). Clinical, biochemical, imagin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically confirmed phosphaturic mesenchymal tumor (PMT). Clinically and biochemically confirmed tumor-induced osteomalacia (TIO). Availability of complete histopathological and clinical routine data, including imaging and surgical documentation.

Exclusion criteria

Exclusion criteria: Missing or insufficient histopathological or clinical records preventing assessment of the primary study endpoints. Tumors without evidence of tumor-induced osteomalacia or without histological confirmation of a phosphaturic mesenchymal tumor.

Design outcomes

Primary

Measure	Time frame
Comprehensive clinicopathologic characterization of phosphaturic mesenchymal tumors (PMTs) associated with tumor-induced osteomalacia (TIO), including histopathological, immunohistochemical, and molecular (DNA- and RNA-based) findings and their correlation with clinical characteristics.	—

Secondary

Measure	Time frame
Characterization of the clinical presentation, biochemical parameters (including serum phosphate and FGF23), and imaging findings. Correlation of histopathological features with molecular alterations (e.g., FN1::FGFR1 fusions) and clinical parameters. Evaluation of the impact of preoperative arterial embolization on tumor histomorphology. Description of surgical outcomes and postoperative biochemical and clinical recovery. Exploration of associations between molecular findings and clinicopathological characteristics.	—

Measure

Time frame

Characterization of the clinical presentation, biochemical parameters (including serum phosphate and FGF23), and imaging findings. Correlation of histopathological features with molecular alterations (e.g., FN1::FGFR1 fusions) and clinical parameters. Evaluation of the impact of preoperative arterial embolization on tumor histomorphology. Description of surgical outcomes and postoperative biochemical and clinical recovery. Exploration of associations between molecular findings and clinicopathological characteristics.

—

Countries

Germany

Contacts

Public ContactLothar Seefried

Universitätsklinikum Würzburg Osteologie / Kliniksche Studieneinheit

lothar.seefried@klh.de00499318033575

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026